At NorthStar Medical Radioisotopes, our mission is to provide patients global access to game-changing radiopharmaceuticals. We are a growing, commercial-stage company focused on advancing patient care by providing therapeutic radioisotopes and novel radiopharmaceuticals to detect and treat cancer, and customized radiopharmaceutical development services. Radiopharmaceutical therapy is increasingly important for cancer treatment, and NorthStar is expanding our industry-leading position in developing commercial-scale production technologies to meet this important healthcare need. We routinely produce the therapeutic radioisotope copper-67 (Cu-67) and are poised to be one of the first commercial-scale producers of non-carrier-added (n.c.a.) actinium-225 (Ac-225), using first-in-kind and environmentally preferable electron accelerator technology. NorthStar’s Radiopharmaceutical Contract Development and Manufacturing Organization (CMDO/CMO) unit provides customized service offerings and specialized radiopharmaceutical expertise to help biopharmaceutical companies rapidly advance their development and commercial programs. At NorthStar, we prioritize professional growth of our employees. Working with our cutting-edge technology offers a stimulating and rewarding environment for talented individuals who want to be part of our exciting and growing business. We are committed to providing our employees with fulfilling work experiences and valuable career development opportunities.